*Two single-blind, Phase III trials comparing ARESTIN® + SRP to SRP alone and SRP + placebo (n=748). SRP was performed for all groups at baseline. ARESTIN® or vehicle was administered to periodontal pockets ≥5 mm in the adjunctive therapy groups at baseline, 3 months, and 6 months. Efficacy was evaluated over 9 months.
REFERENCES: 1. ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg. Prescribing Information. Horsham, PA: OraPharma, Inc.; 2011. 2. Williams RC. Medical progress: periodontal disease. New Engl J Med. 1990;322(6):373-380.